Soleno Therapeutics will present at two investor conferences in February 2025 regarding its rare disease therapeutics.
Quiver AI Summary
Soleno Therapeutics, Inc. announced its participation in two upcoming investor conferences in February 2025. The company will host a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6 and a corporate presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11. Both events will include webcasts available for replay on Soleno's website. Soleno is focused on developing treatments for rare diseases and is currently awaiting FDA review of its lead candidate, DCCR, for Prader-Willi syndrome.
Potential Positives
- Participation in two significant investor conferences enhances visibility and engagement with potential investors.
- FDA’s Priority Review status for the NDA of DCCR highlights the potential of the company’s lead candidate and accelerates the pathway to market.
Potential Negatives
- Participation in investor conferences may raise concerns about the company's need to attract investor attention amidst ongoing FDA review processes and upcoming presentations.
- The focus on rare diseases and the development of a single lead candidate could indicate a limited product pipeline, which may concern investors about long-term growth potential.
- The press release does not provide updates on the status of the NDA under FDA review, which could signal uncertainty or lack of progress in obtaining regulatory approval.
FAQ
When will Soleno Therapeutics participate in investor conferences?
Soleno Therapeutics will participate in investor conferences on February 6 and February 11, 2025.
What type of presentation format will Soleno use at the conferences?
The presentations will be in a Fireside Chat format on February 6 and a Corporate Presentation format on February 11.
How can I access the webcasts of Soleno's presentations?
You can access the webcasts via the provided links: Guggenheim conference and Oppenheimer conference webcasts.
Where can I find replays of the presentations?
Replays of both presentations will be available in the Investors section of Soleno's website, www.soleno.life.
What is Soleno's lead candidate for rare diseases?
Soleno's lead candidate is DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SLNO Insider Trading Activity
$SLNO insiders have traded $SLNO stock on the open market 59 times in the past 6 months. Of those trades, 0 have been purchases and 59 have been sales.
Here’s a breakdown of recent trading of $SLNO stock by insiders over the last 6 months:
- OPPORTUNITY, LLC VIVO has made 0 purchases and 3 sales selling 1,025,000 shares for an estimated $49,210,750.
- BHATNAGAR ANISH (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 14 sales selling 285,072 shares for an estimated $13,296,225.
- JAMES H MACKANESS (CHIEF FINANCIAL OFFICER) has made 0 purchases and 14 sales selling 44,465 shares for an estimated $2,084,686.
- KRISTEN YEN (SEE REMARKS) has made 0 purchases and 14 sales selling 29,647 shares for an estimated $1,384,253.
- PATRICIA C HIRANO (SEE REMARKS) has made 0 purchases and 14 sales selling 27,852 shares for an estimated $1,302,074.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SLNO Hedge Fund Activity
We have seen 99 institutional investors add shares of $SLNO stock to their portfolio, and 41 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VIVO CAPITAL, LLC removed 1,025,000 shares (-14.0%) from their portfolio in Q3 2024, for an estimated $51,752,250
- ALYESKA INVESTMENT GROUP, L.P. added 976,105 shares (+inf%) to their portfolio in Q3 2024, for an estimated $49,283,541
- PRICE T ROWE ASSOCIATES INC /MD/ added 831,643 shares (+174.0%) to their portfolio in Q3 2024, for an estimated $41,989,655
- ASSENAGON ASSET MANAGEMENT S.A. removed 729,841 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $36,849,672
- JANUS HENDERSON GROUP PLC added 722,226 shares (+21.5%) to their portfolio in Q3 2024, for an estimated $36,465,190
- FMR LLC added 665,363 shares (+6048754.5%) to their portfolio in Q3 2024, for an estimated $33,594,177
- WESTFIELD CAPITAL MANAGEMENT CO LP added 495,708 shares (+inf%) to their portfolio in Q3 2024, for an estimated $25,028,296
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February:
Guggenheim SMID Cap Biotech Conference
Presentation Date:
Thursday, February 6, 2025 at 2:00 PM ET
Presentation Format:
Fireside Chat
Webcast:
https://wsw.com/webcast/guggen2/slno/2028708
Oppenheimer 35
th
Annual Healthcare Life Sciences Conference
Presentation Date:
Tuesday, February 11, 2025 at 2:40 PM ET
Presentation Format:
Corporate Presentation
Webcast:
https://wsw.com/webcast/oppenheimer39/slno/2814816
A replay of both events will be available in the Investors section on the Company’s website at www.soleno.life .
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life .
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578